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Several genome-wide transcriptomics efforts have shown that a large percentage of the mammalian genome is transcribed into
RNAs, however, only a small percentage (1–2%) of these RNAs is translated into proteins. Currently there is an intense interest in
characterizing the function of the different classes of noncoding RNAs and their relevance to human disease. Using genomic
approaches we discovered FMR4, a primate-specific noncoding RNA transcript (2.4 kb) that resides upstream and likely shares a
bidirectional promoter with FMR1. FMR4 is a product of RNA polymerase II and has a similar half-life to FMR1. The CGG expansion in
the 59 UTR of FMR1 appears to affect transcription in both directions as we found FMR4,s i m i l a rt oFMR1, to be silenced in fragile X
patients and up-regulated in premutation carriers. Knockdown of FMR4 by several siRNAs did not affect FMR1 expression, nor vice
versa, suggesting that FMR4 is not a direct regulatory transcript for FMR1. However, FMR4 markedly affected human cell
proliferation in vitro;s i R N A sk n o c k d o w no fFMR4 resulted in alterations in the cell cycle and increased apoptosis, while the
overexpression of FMR4 caused an increase in cell proliferation. Collectively, our results demonstrate an antiapoptotic function of
FMR4 and provide evidence that a well-studied genomic locus can show unexpected functional complexity. It cannot be excluded
thatalteredFMR4 expressionmightcontributetoaspectsoftheclinicalpresentationoffragileXsyndromeand/orrelateddisorders.
Citation: Khalil AM, Faghihi MA, Modarresi F, Brothers SP, Wahlestedt C (2008) A Novel RNA Transcript with Antiapoptotic Function Is Silenced in
Fragile X Syndrome. PLoS ONE 3(1): e1486. doi:10.1371/journal.pone.0001486
INTRODUCTION
While at least 40–50% of the human genome is transcribed into
RNA, only 1.2% of the genome is translated into protein [1–3].
RNAs which do not code for proteins (noncoding RNAs) have been
classified into different classes (tRNA, rRNA, snRNA, snoRNA,
miRNA, siRNA, piRNA, natural antisense transcripts and long
noncoding RNA) based on their size and function. Novel classes of
noncoding RNAs have been shown to have a variety of functions
which include translational inhibition (miRNA) [4], mRNA
degradation (siRNA) [5], and repressing transposition (piRNA)
[6,7]. Also, thousands of protein coding genes have now been shown
to have antisense transcripts [8]. Antisense transcript manipulation
can in some cases lead to the repression of the sense transcript
(discordant regulation) or enhance the stability of the sense transcript
(concordant regulation) [8]. However, the exact mechanisms by
which antisense transcripts regulate their sense partners are likely
diverse and require further studies. Another class of noncoding
RNAs is long noncoding RNAs (or ‘‘macroRNA’’) [9,10] which do
not overlap with protein-coding genes and range from 300
nucleotides to over 10 kb in size with an average size of ,2k b
[9,11]. Notably, the sequence of noncoding RNAs, in contrast to
other noncoding RNAs such as miRNAs and snoRNAs, is often not
well conserved even between mammals [9] and can function both in
cis (e.g., XIST)[ 1 2 ]a n din trans (e.g., HOTAIR)[ 1 3 ] .I nc o n t r a s tt o
other noncoding RNAs, only a small number of long noncoding
RNAs have been functionally characterized. Several studies have
now shown that the expression pattern of noncoding RNAs can be
altered in several human diseases such as cancers and heart disease
[14,15] suggesting that noncoding RNAs may have a functional
relevance to human disease and that they may be considered as
potential drug targets [11,16].
Fragile X syndrome (FXS), the most common cause of inherited
mental retardation, is caused by the expansion of CGG trinucleotide
repeats in the 59 UTR of the fragile X mental retardation 1 gene
(FMR1) [17–19]. Normal individuals have a range of 5–50 CGG
repeats in the 59 UTR of FMR1 and express FMR1 in a wide range
ofadultandembryonictissues[20].TheCGGrepeatscanexpandin
the female germ line or shortly after fertilization by an unknown
mechanism. Individuals with 55–200 repeats are premutation
carriers and generally express higher levels of FMR1 mRNA than
normal individuals and may result in a clinical condition termed
fragile X tremor and ataxia syndrome (FXTAS) [21,22]. The
expansion of CGG repeats above 200 leads to the repression or
silencing of FMR1 and consequently to the absence of the fragile X
mentalretardationprotein(FMRP).Wehavepreviouslybeen partof
effort to identify and characterize 2,113 bidirectional promoters
from 42,887 transcriptional units in humans [23]. In the present
manuscript, we report the discovery and functional characterization
of a primate-specific noncoding RNA (FMR4) that becomes silenced
as a result of the CGG expansion in the 59 UTR of FMR1 in fragile
Xs y n d r o m e .In vitro manipulation of FMR4 indicates it has an
antiapoptotic function in human cells.
RESULTS
Identification and expression analysis of FMR4
Previous work by us and others has shown that bidirectional
promoters are relatively common in the mammalian genome
[8,23]. Therefore, using genomic approaches, including rapid
amplification of cDNA ends (RACE), regular and real time PCR
(RT-PCR), we searched for transcripts upstream of FMR1 that
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report the identification of a novel 2.4 kb long noncoding RNA,
which we named FMR4, that resides upstream and likely shares a
bidirectional promoter with FMR1 (Figure 1A–B). Bioinformatic
analysis suggests that FMR4 does not have a conventional open
reading frame, to confirm that FMR4 is indeed a noncoding RNA
we carried out in vitro transcription/translation followed by mass
spectrometry analysis; however, no protein was detected suggesting
that FMR4 is most likely a noncoding RNA (data not shown).
Northern blot analysis shows that FMR1 is expressed in the
majority of the human tissues examined consistent with previous
reports [20]. FMR4 is expressed in several adult human tissues
including brain, liver, placenta, small intestine, colon and spleen
but not in the pancreas, testes, ovaries or prostate (Figure S1). Two
bands corresponding to FMR4 were observed in several human
adult tissues, one possibility is that there is alternative transcription
start sites for FMR4, however, when we performed our RACE
analysis we used RACE ready cDNA from SH-SY5Y cells and
obtained only the longer 2.4 kb transcript.
FMR4 is ubiquitously expressed during human
development
Since FMR4 is expressed in several human adult tissues, we next
examined its expression levels in human fetal tissues. Using RT-
PCR we measured RNA expression levels of FMR4 in seven
Figure 1. Identification and sequence analysis of FMR4. (A) Schematic showing known genes in Xq27.3-28 including the newly identified FMR4.
FMR4 is transcribed upstream of FMR1 and in the opposite direction. (B) Sequence of FMR4 obtained by rapid amplification of cDNA ends (RACE).
doi:10.1371/journal.pone.0001486.g001
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was pooled from at least three different embryos (GBiosciences).
We found FMR4 to be expressed in all the tissues examined
including the brain. Notably, FMR4 is highly expressed in the
kidney and heart at that stage of human development (Figure 2A).
The high expression of FMR4 in the heart is consistent with a
previous report that patients with fragile X syndrome have cardiac
defects similar to those seen in other disorders of connective tissue
such as Marfan’s syndrome and Ehlers-Danlos syndrome [24].
FMR4 is expressed in human and monkey brain
To determine whether FMR4 shows differential expression within
different regions of the human brain, we examined the RNA
concentrations of both FMR1 and FMR4 by Real-Time PCR (RT-
PCR) using tissue from six postmortem human brains (from four
males and two females aged 61–91 years) and studied three
different regions (cerebellum, frontal cortex, and hippocampus).
By this quantitative method, RT-PCR, both FMR1 and FMR4
were shown to display robust expression levels in all three brain
regions tested (Figure 2B). To determine if FMR4 is also expressed
in other primates, we examined the expression of FMR4 in rhesus
monkey brain regions using RT-PCR. Total RNA from each
brain region was isolated from two monkeys and DNAse treated
prior to cDNA synthesis. We found FMR4 to be expressed in all
the monkey brain regions tested with high expression in the
cerebellum and interior parietal cortex (Figure 2C) confirming that
FMR4 is expressed in other primates in addition to humans.
The CGG expansion affects transcription in both
directions of a bidirectional promoter
To determine if the expression of FMR4 is affected by the CGG
expansion in the 59 UTR of FMR1 that occurs in FXS and/or
FXTAS, we investigated the relative expression of FMR4 and
FMR1 by RT-PCR in untransformed leukocytes from four control,
four premutation and four FXS patients. We found FMR4
expression, similar to FMR1, to be significantly up-regulated in
premutation carriers, and shut down in full mutation (FXS)
patients (P,0.0001) (Figure 3A). All the samples tested had a
matching control without the reverse transcriptase to account for
Figure 2. Expression analysis of FMR4. (A) RT-PCR analysis of FMR4 and FMR1 in seven different human fetal tissues (week 12), RNA from each tissue
was pooled from at least three fetuses (GBiosciences). The RNA expression of FMR1 and FMR4 were normalized to whole embryo (set as 100%). Both
transcripts are expressed in all the tissues tested with notably high expression of FMR4 in the kidney and heart. (B) RNA was extracted from six
postmortem human adult brains from three different regions, thereafter; cDNA synthesis followed by RT-PCR was performed on all samples to
measure the relative quantities of FMR1 and FMR4. Both FMR1 and FMR4 are highly expressed in all the human brain regions tested. (C) RT-PCR
analysis of FMR4 and FMR1 in several regions of two monkeys brains. The RNA expression of FMR4 and FMR1 were normalized to the insula (set as
100%).
doi:10.1371/journal.pone.0001486.g002
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cycles), gel electrophoresis and ethidium bromide staining to
examine the expression of FMR4 and FMR1 from the same
samples. FMR4 was detectable in both the normal and premuta-
tion carriers but not in the full mutation fragile X patients. FMR1
was detectable in the normal, premutation carriers and one out of
the four fragile X patients (Figure 3B); this is not surprising since
variable levels of FMR1 mRNA have been previously shown to be
present in some fragile X patients [25].
FMR4 is a product of RNA polymerase II and has a
similar half-life to FMR1
To measure the relative half-lives of FMR1 and FMR4 we treated
HEK-293T cells with 50 mMo fa-amanitin (an inhibitor of RNA
polymerase II) [26] and RNA was isolated at 0, 6, 12 and 24 hours
post treatment (six repeats each). All treated samples had a
matching control which did not receive a-amanitin (untreated
samples). Actin was used as a positive control and 18S rRNA was
used as a negative control (a product of RNA polymerase I). By
RT-PCR we measured the levels of Actin, 18S, FMR1, and FMR4.
As expected 18S rRNA levels did not change at any of the time
points tested since a-amanitin does not affect RNA polymerase I.
By contrast Actin, FMR1 and FMR4 were all affected since they are
all products of RNA polymerase II. The data indicates that FMR4
has a similar half-life to FMR1 (Figure 4).
No evidence of direct cross-regulation between
FMR1 and FMR4
To determine whether FMR1 and FMR4 are functionally linked,
we tested three different siRNAs against FMR1 and identified
three different newly designed siRNAs against FMR4.I ti s
important to utilize multiple efficacious siRNAs to any given
target in order to avoid the possibility of off-target phenomena
[11,27]. Also, since FMR4 is highly expressed in human embryonic
kidney (Figure 2A), we decided to use HEK-293T cells as an in vitro
system to study FMR4 regulation and function. First, we tested
three siRNAs against FMR1 by transfecting HEK-293T cells with
20 nM (final concentration) of FMR1 siRNAs (six repeats each).
Two out of the three siRNAs tested were effective in knocking
down FMR1 by 80% as early as 48 hours post transfection (siRNA
B and C, Table 1). This level of knockdown was also observed at
72 hours post transfection and in repeated transfection experi-
ments (144 hours total, two transfections at 0 hour and 72 hours
post first transfection). However, in all cases the concentrations of
FMR4 were not affected by FMR1 siRNAs (Figure 5A). We
designed and tested nine different siRNAs for FMR4, three
siRNAs (C, G, and H, see methods for sequences) caused a
significant decrease in FMR4 at 48 and 72 hours post transfection,
but did not affect the levels of FMR1 (Figure 5B). We used FMR4
siRNA C which caused the highest level of FMR4 knockdown
among the siRNAs tested for a time course experiment. HEK-
293T cells were transfected with FMR4 siRNA C and RNA was
collected at 24, 48, 72 and 144 hours post transfection. This
siRNA caused a significant knockdown of FMR4 but did not affect
FMR1 levels at any of the time points tested (Figure 5C). We next
cloned FMR4 into a pcDNA3.1 vector with a CMV promoter and
overexpressed FMR4 in HEK-293T cells, a pcDNA3.1 vector
without the FMR4 insert was used as a control. At 72 hours post
Figure 3. FMR4 is silenced in fragile X syndrome. (A) RNA from four
normal, four premutation and four full mutation FXS patients isolated
from untransformed leucocytes (kindly provided by Flora Tassone and
Paul Hagerman, UC Davis) was reverse transcribed using random
hexamers. Quantitative RT-PCR analysis revealed that FMR4, similar to
FMR1, is up-regulated in pre-mutation carriers and shut down in full
mutation fragile X patients (P,0.0001). (B) RNA from untransformed
leucocytes were reversed transcribed and the cDNA was used for PCR
analysis. FMR4 is expressed in normal and premutation carriers but no
bands were observed in the full mutation fragile X patients (35 cycles).
FMR1 bands were observed in normal, premutation, and one of the full
mutation patients (35 cycles). To account for any possible DNA
contamination, no reverse transcriptase control for all samples were
used in the PCR (lanes next to bands are all negative indicating no DNA
contamination was present). Error bars: s.d.
doi:10.1371/journal.pone.0001486.g003
Figure 4. FMR4 has a similar half-life to FMR1. HEK-293T cells were
treated with a-amanitin (blocks RNA polymerase II) and the levels of
FMR4 and FMR1 were measured by RT-PCR at 0, 6, 12 and 24 hours post
treatment. Both FMR4 and FMR1 have similar half-lives. These
experiments also further confirm that FMR4 is a product of RNA
polymerase II.
doi:10.1371/journal.pone.0001486.g004
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RT-PCR analysis. As expected, FMR4 overexpression led to a
substantial increase in FMR4 RNA levels, but did not have any
effect on FMR1 RNA (Figure 5D). Collectively, these experiments
suggest that the non-overlapping transcripts FMR1 and FMR4 do
not regulate each other.
FMR4 affects cell proliferation in human cells
To uncover a possible function for FMR4, we examined the effects
of three distinct and efficacious siRNAs against FMR4 on cell
proliferation using a luciferase reporter system (see methods).
HEK-293T cells were transfected with either siRNAs targeting
FMR4 (C, G, and H), FMR1, or a control siRNA. All cells were
simultaneously co-transfected with a pGL3 (luciferase) vector. At
72 hours post transfection, luciferase activity, which is a marker of
cell proliferation, was measured using an Analyst GT Multimode
Reader (Molecular Devices) and all data points were plotted as a
percentage of control siRNA treated cells. All three siRNAs
against FMR4, but not the siRNA against FMR1, resulted in
significant decreases in cell proliferation in comparison to the
control siRNA treated cells (Figure 6A). To determine if the effect
of FMR4 on cell proliferation is reproducible in other human cell
lines we carried out a similar experiment using HeLa cells and
found that all three siRNAs against FMR4 also resulted in highly
significant decreases in cell proliferation in comparison to control
siRNA (P,0.0001) (Figure 6B). In contrast to HEK-293T cells,
FMR1 siRNA resulted in a marginally significant decrease in cell
proliferation in HeLa cells (Figure 6B). We also carried out a
Figure 5. No direct cross-regulation between FMR1 and FMR4. (A) We used three distinct siRNAs against FMR1 to transfect HEK-293T cells. Two out
of the three siRNAs resulted in a significant knockdown of FMR1 (80%), but did not affect FMR4 RNA levels. (B) We used three distinct siRNAs against
FMR4 to transfect HEK-293T cells. All three siRNAs resulted in a significant knockdown of FMR4 but did not affect FMR1 RNA levels. (C) Significant
knockdown of FMR4 via siRNA C did not result in a change in FMR1 RNA levels at any of the time points tested (24, 48, 72, or 144 hours post
transfection). (D) The entire sequence of FMR4 was cloned into a pcDNA3.1 vector with a CMV promoter. The pcDNA3.1 vector containing the FMR4
sequence and the original pcDNA3.1 (without the FMR4 insert) were transfected in HEK-293T cells. At 72 hours post transfection, RNA was isolated
and reversed transcribed and used for RT-PCR analysis. There is a highly significant increase in the FMR4 RNA levels but no effect on FMR1 RNA. Error
bars: s.d.
doi:10.1371/journal.pone.0001486.g005
Table 1. Sequences of FMR1 and FMR4 siRNAs.
......................................................................
siRNA Sequence Supplier
FMR1 A GGUGUAUUCCAGAGCAAAUtt Ambion (ID # 10824)
FMR1 B GGGUGAGUUUUAUGUGAUAtt Ambion (ID # 11010)
FMR1 C GGAUGAUAAAGGGUGAGUUtt Ambion (ID # 10919)
FMR4 A GCCCUCUCUCACCAGAUUUtt QIAGEN
FMR4 B AGGGCCAGAACGCCCAUUUtt QIAGEN
FMR4 C GUGGCGUGGGAAAUCAAAUtt QIAGEN
FMR4 D GCAUCCGGUUAUCCCAGUUtt Invitrogen
FMR4 E UCGCCUUUCCUCAACUCAUtt Invitrogen
FMR4 F GCACUUGAGGUUCAUUUCUtt Invitrogen
FMR4 G AGAGAUCCUUGAUAAUUUAtt QIAGEN
FMR4 H CAUUGAUUAGAAUGAUUAUtt QIAGEN
FMR4 I GUAGGUGGACAUAAAUCAAtt QIAGEN
doi:10.1371/journal.pone.0001486.t001
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negative control experiment and as expected siRNAs against
FMR4 had no effect on cell proliferation in mouse N2A cells
(Figure 7A). To determine if the overexpression of FMR4 have an
opposite effect compared to FMR4 siRNAs knockdown on cell
proliferation, we next transfected HEK-293T and HeLa cells with
FMR4 overexpression vector. We found that the overexpression of
FMR4 in both cell lines resulted in an increase in cell proliferation
compared to the control vector treated cells (P,0.0001)
(Figure 6C–D). The overexpression of FMR4 in mouse N2A cells
had no effect on cell proliferation (Figure 7B).
FMR4 has antiapoptotic properties
To further characterize the manner in which FMR4 affects cell
proliferation, we knocked down FMR4 using two different siRNAs
(four repeats each), and we used a control negative siRNA (four
repeats also) to examine the effects of FMR4 on the cell cycle in
HEK-293T cells. At 72 hours post transfection, we performed
propidium iodide FACS analysis (see methods) and found that the
siRNAs knockdown of FMR4 resulted in an increase in the
number of cells in the Sub-G1 phase and a modest but significant
decrease in the number of cells in S phase of the cell cycle
(Figure 8A). This suggested that FMR4 may have an antiapoptotic
function in human cells; therefore, we next performed a
fluorescent TUNEL assay and found a significant increase in
apoptosis in cells treated with FMR4 siRNA (72 hours post
transfection) compared to cells treated with a control siRNA,
further indicating that FMR4 has an antiapoptotic function in
human cells (Figure 8B–C).
DISCUSSION
In the present manuscript we report the discovery of a 2.4 kb
noncoding RNA (FMR4) which is transcribed upstream of FMR1.
There is no overlap between the FMR1 and FMR4 transcripts, and
therefore, FMR4 is not a natural antisense transcript to FMR1.
FMR4 is expressed in human adult and fetal tissues, and in several
regions of human and rhesus monkey adult brain but at varying
concentrations. Despite the likelihood that FMR4 shares a
bidirectional promoter with FMR1, FMR4 is not expressed in the
adult testes, ovary and prostate where FMR1 is highly expressed. It is
possible however that FMR4 is expressed in these tissues during
embryonic and/or fetal development as the RNAs used in our
Figure 6. FMR4 affects proliferation in human cells. (A) Cell proliferation assay showing that the knockdown of FMR4 via three distinct siRNAs in
HEK-293T cells, but not knockdown of FMR1, resulted in decrease in cell proliferation in comparison to cells which are treated with a negative control
siRNA. Cell proliferation was measured based on luciferase activity in these cells at 72 hours post siRNA transfection. (B) Cell proliferation assay
showing that the knockdown of FMR4 via three distinct siRNAs in HeLa cells resulted in decrease in cell proliferation in comparison to cells which are
treated with a negative control siRNA (P,0.0001). (C–D) In both HEK-293T and HeLa cells, overexpression of FMR4 resulted in an increase in cell
proliferation in comparison to cells treated with a control vector. Error bars: s.d.
doi:10.1371/journal.pone.0001486.g006
Antiapoptotic RNA Transcript
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obtained from human adults. Notably, we found FMR4 to be highly
expressed in fetal heart and kidney. The cardiac expression of FMR4
may possibly be of functional relevance considering the fact that
many patients with fragile X syndrome exhibit heart defects such as
dilation of the aortic root and mitral valve prolapse [24,28].
Moreover the high expression of FMR4 in the kidney (Figure 2A)
appears consistent with our observations that the human embryonic
kidney cell line, HEK-293, also expresses FMR4.
Bioinformatics analysis shows that the genomic sequence
encompassing FMR4 is conserved in other primates (chimp and
rhesus monkey) with only partial homology to the mouse (Figure
S2). Interestingly, however, there is an apparent transcript in the
mouse X chromosome that is on the minus strand that starts
approximately 100 bp upstream of the mouse Fmr1 gene. This
transcript (NCBI accession number AK148387) does not have
significant homology with the human FMR4 transcript (,3%
nucleotide identity by ClustalW using default analysis parameters
for nucleotide sequences). Furthermore, this mouse transcript
appears to be highly spliced and contains 4 exons, which is an
additional distinction from the human FMR4 transcript. However,
we can not rule out that FMR4 and AK148387, despite their
genomic differences, still perform a similar function. The majority of
noncoding RNAs identified to date seem to be poorly conserved
even among mammals; this is in contrast to other noncoding RNAs
(e.g., microRNAs and snoRNAs) which show a high level of
conservation among diverse species [9]. It is worth noting that while
the human and mouse Xist show 66% homology [29]; however,
there seems to be rapid evolution of unique sequences [30]. Also,
several attempts to find an orthologue for XIST in marsupials have
failed [31,32] despite the fact that imprinted X inactivation still
occurs in marsupials, a process that requires XIST in eutharians [33]
suggesting the possibility that a non-conserved noncoding RNA in
marsupials may perform a similar function to XIST.
We found that FMR4 regulates human cell proliferation in vitro;
knockdown of FMR4 resulted in alterations in the cell cycle and
apoptosis while the overexpression of FMR4 leads to an increase in
cell proliferation. While the involvement of poorly studied protein
coding gene(s) within the FMR1 genomic locus cannot be excluded
at this time, our results suggest that the FMR4 function involves a
noncoding mechanism. Recently, a long noncoding RNA, similar
in size to FMR4, was identified in the HOXC locus (HOTAIR) [13].
The HOTAIR noncoding RNA represses transcription in trans
across 40 kb of the HOXD locus by altering the chromatin
modifications through enhancement of the PCR2 activity at the
HOXD locus [13]. It is therefore possible that FMR4 may also
target a set of genes in trans resulting in its antiapoptotic properties.
In conclusion, our findings should add further evidence that novel
nonconserved noncoding RNAs may be functional and that they
do not simply represent ‘‘transcriptional noise’’.
While our manuscript was under review, Ladd et al. published on
an antisense transcript that spans the CGG repeats in the 59 UTR
of FMR1 [34]. This transcript, ASFMR1, is up-regulated in
premutation carriers and shut down in fragile X patients similar
to FMR1 and FMR4. Also, one splice variant of ASFMR1 overlaps
with FMR4, therefore it is possible that FMR4 is nested in the 39
UTR of ASFMR1, a phenomenon seems to be prevalent in many
genes throughout mammalian genomes [1] or another possibility is
that these two transcripts may also have contiguous isoforms which
is another intriguing possibility. ASFMR1 appears to be highly
spliced and has multiple transcription start sites. One transcription
start site is in intron 2 of FMR1 at position +10243. This
transcription start site was identified by utilizing a 59 RACE primer
in exon 1 of FMR1. Also, multiple transcription start sites for
ASFMR1 were also identified in 299 to 2208 upstream of FMR1
by designing 59 RACE primers in the 21000 position relative to
FMR1. From these experiments it is not clear if the transcript which
starts in the +10243 is the same transcript as the one that initiates in
the 299 to 2208. If these two transcripts were both ASFMR1, the
authors should have been able to clone the longer transcript which
initiates at +10243 using the 59 RACE primers which they used to
identify the multiple transcription start sites in the 299 to 2208
positions. Therefore, another possibility is that one of the
transcripts that Ladd et al. cloned and identified as an alternative
transcript to ASFMR1 is the FMR4 transcript. In essence, our
findings along with Ladd et al. suggest a complex transcription
within the FMR1 locus than previously thought and should provide
an incentive for further studies to determine the exact nature of all
the transcripts, and their function, throughout the FMR1 region
Figure 7. The effect of FMR4 on cell proliferation is not observed in
non-primates. Since FMR4 is a primate-specific transcript we examined
its effect on cell proliferation in non-primates using mouse N2A cells.
We examined both the siRNA knockdown of FMR4 (as a negative
control experiment) and the over-expression of FMR4 on cell
proliferation in N2A cells. (A) Mouse N2A cells were transfected with
FMR4 siRNA C and a control siRNA. Simultaneously, cells were
transfected with pGL3 (luciferase) vector. At 72 hours post transfection
luciferase activity was measured and data are graphed as a percentage
of control siRNA. (B) Mouse N2A cells were transfected with FMR4 over-
expression vector and a control vector (no FMR4 insert). Simultaneously,
cells were transfected with pGL3 (luciferase) vector. At 72 hours post
transfection luciferase activity was measured and data are graphed as a
percentage of control vector. Unlike human cells which show an
increase in cell proliferation when transfected with the FMR4 vector,
mouse N2A cells did not show any change in proliferation.
doi:10.1371/journal.pone.0001486.g007
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syndrome and FXTAS).
MATERIALS AND METHODS
Rapid amplification of cDNA ends (RACE)
The genomic sequence for FMR1locus wasobtained from the UCSC
website (http://genome.ucsc.edu/). RACE-ready cDNA (0.5 ng/ml)
from SH-SY5Y cells for 59 and 39 RACE was custom made by
Ambion (Austin, TX). RACE primers were designed using Primer3
software and the name and sequence of the RACE primers for FMR4
is listed here: FMR4 59 outer 1: TGAGTTGAGGAAAGGCGAGT;
FMR4 59 inner 1: TTGAGATCCCGACTCAATCC. We carried
out two rounds of PCR using the outer and inner primers
sequentially. First PCR was carried out using 10 ml of RACE-ready
cDNA and the second PCR was carried out using 2 ml of the first
PCR product. PCR conditions were as follow: 94 C for 5 minutes,
( 9 4Cf o r3 0s e c o n d s ,5 9Cf o r3 0s e c o n d s ,7 2Cf o r2m i n u t e s )f o r3 5
cycles, 72 C for 10 minutes. Both first and second PCR products
were ran on a 2% agarose gel and bands of interestwere cut, purified,
cloned into pGEM T-easy vector (Promega, Madison, WI) before
sequencing (UC Davis Sequencing Core Facility).
Figure 8. FMR4 has an antiapoptotic function in human cells. (A) Cell cycle analysis of control cells (red) and cells treated with two different siRNAs
against FMR4 (green and blue) shows that knockdown of FMR4 resulted in a highly significant increase in the number of cells in Sub-G1 and a modest
but significant decrease in the number of cells in the S phase suggesting a possible role in apoptosis. (B) Microscope images of cells (DAPI stained)
treated with a control siRNA and cells treated with FMR4 siRNA for 72 hours prior to a TUNEL assay. A significant number of cells are undergoing
apoptosis (FITC) in the FMR4 siRNA treated cells in comparison to the control siRNA treated cells. (C) Quantification of cells following a TUNEL assay
indicated that there is at least a two-fold change in the number of cells undergoing apoptosis in the FMR4 siRNA treated cells in comparison to the
control siRNA treated cells. Error bars: s.d.
doi:10.1371/journal.pone.0001486.g008
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Total RNA was extracted using Quiagen RNeasy mini kit
(catalogue # 74106). RNA concentrations were measured using
The NanoDropH ND-1000 UV-Vis Spectrophotometer. Equal
amounts of RNA were reversed transcribed using TaqMan reverse
transcription reagents (part # N808-0234) according to the
manufacturer’s protocol.
Real-Time PCR
FMR4 forward primer: ACACCCTGTGCCCTTTAAGG, FMR4
reverse primer: TCAAAGCTGGGTCTGAGGAAAG, Reporter
(probe): TCGGGATCTCAAAATGT. Real-Time PCR (RT-
PCR) was carried out with the GeneAmp 7900 (Applied
Biosystems, Foster City, CA). The PCR reactions contained 20–
40 ng cDNA, Universal Mastermix (Applied Biosystems, Foster
City, CA), 300 nM of forward and reverse primers, and 200 nM of
probe in a final reaction volume of 15 ml. The primers and probe
were designed using File-Builder software (Applied Biosystems,
Foster City, CA). The PCR conditions were as follows: 50 C for
2 min then 95 C for 10 min then 40 cycles of 95 C for 15 s and 60
C for 1 min. The results are based on cycle threshold (Ct) values.
Differences between the Ct values for experimental and reference
genes (18srRNA) were calculated as DDCt.
In vitro transcription and translation
1 ug of pcDNA3.1 containing the FMR4 sequence (or without the
sequence as a control) was utilized for in vitro transcription using a
MAXIscript kit (Cat # AM1200, Ambion, Austin, TX) according
to manufacturer’s instructions. Subsequently, in vitro translation
was carried out using the Retic Lysate IVT kit (Ambion, Austin,
TX) according to manufacturer’s instructions, except that
Fluorotect Green-Lys (Promega, Madison, WI) was included in
the translation mixture according to manufacturer’s suggestions.
Fluorotect Green-Lys, is a BIODPY labeled lysine that allows the
addition of a fluorescent amino acid to any newly synthesized
peptide (unlabeled lysine is also included in the reaction mixture)
allowing for fluorescent detection of such peptides.
Northern blot analysis We purchased a human ready-to-
hybridize northern blot membrane from Ambion (cat# 3141)
which has 2 mg of poly(A) RNA per lane isolated from human
brain, liver, placenta, small intestine, colon, pancreas, spleen,
prostate, testes, and ovary. The membrane was initially incubated
with 15 ml of pre-warmed hybridization solution (Ambion,
cat#8670) for 1 hour at 65 C. Northern blot probes (
32P) were
generated using Amersham rediprime II random prime labeling
system (RPN1633) according to the manufacturer’s protocol (GE
Healthcare, Piscataway, NJ). We added 14 ml of the probe per
5 ml of hybridization buffer (42 ml total) to the membrane for
overnight incubation at 42 C. Two low-stringency and two high-
stringency washes were performed for 15 minutes each prior to
exposing the membrane for phosphor imager.
Cell culture, siRNA transfection and RNA isolation HEK-
293T and N2A cells were cultured in MEM plus 10% FBS. Cells
in the logarithmic growth phase were transfected with 20 nM of
siRNA using 0.2% Lipofectamine 2000 according to manufacturer’s
instructions (Invitrogen, Carlsbad, CA). Cells were incubated for
72 h or transfected a second time for an additional 72 hours prior to
RNA isolation. RNA was isolated using QIAGEN RNeasy mini-kit
(QIAGEN, Valencia, CA). All samples were treated with RNAse-
free DNase (QIAGEN, Valencia, CA, #79254) for 20 minutes as
described in the manufacturer’s protocol. The sequence of FMR1
and FMR4 siRNAs are listed in table 1.
FMR4 over-expression T h ee n t i r ec D N As e q u e n c eo fFMR4
was cloned into pcDNA3.1 vector. The vector was sequenced to
verify the insertion of the FMR4 sequence. The vector was transfected
into several human and mouse cell lines using standard procedures.
Stability and a-amanitin treatment HEK-293T cells were
cultured in 6 well plates. Twenty-four h later, cells were treated
with 50 mg/ml of a-amanitin (Sigma, St. Louis, MO). Cells were
harvested for RNA isolation and RT-PCR at 0, 6, 12, and
24 hours post treatment. Three independent samples were taken
for each data point and all samples had untreated matching
samples for RNA purification and data analysis.
Cell proliferation assay Using Multidrop 384Titan, 50 ng of
PGL3vector(luciferasevectorwithSV40promoter),20 nMofsiRNA
and transfection reagents (Lipofectamine 2000 0.2% and OptiMEM,
Invitrogen, CA) were plated in 96 well plates. Equal number of cells
(20,000 per well) were added to each well and incubated at 37uCf o r
72 hours. Bright-Glo luciferase reagent (Promega, Madison, WI) was
added to each well and incubated at room temperature for 5 minutes.
Luciferase activity, as a marker of cell proliferation, was measured by
Analyst GT Multimode Reader (Molecular Devices, Sunnyvale, CA)
and plotted against control siRNA.
Cell cycle analysis We knocked down FMR4 using two
different siRNAs (4 repeats each), and we used a control negative
siRNA (4 repeats also) to examine the effects of FMR4 on the cell
cycle. At 72 hours post transfection, we prepared the cells for flow
cytometry as follow: cells were washed with PBS, trypsynized and
centrifuged at 1,000 rpm for 10 minutes. Then the cells were
washed again with PBS before being fixed with 70% ethanol at
220C overnight. The next day the cells were centrifuged, washed
with PBS and re-suspended in 38 mM sodium citrate, 69 mM
propidium iodide and 19 mg/ml RNAse A for flow cytometry
analysis. Results were analyzed using FlowJo analysis software.
TUNEL assay HEK-293T cells were plated on cover slips
prior to treatment with a control siRNA or siRNAs against FMR4.
At 72 hours post transfection, the cells were fixed with 4%
paraformaldehyde (pH 7.4) for 15 min at room temperature,
followed by permeabilization with 0.1% triton-X in PBS. TdT-
mediated dUTP nick end labeling (TUNEL) reaction mixture was
added to the cells and incubated at 37C for 1 hour (Roche,
Indianapolis, IN). The cells were then stained with DAPI and
images were captured using a confocal microscope.
SUPPORTING INFORMATION
Figure S1 Northern blot analysis of FMR1 and FMR4 in human
adult tissues. FMR1 and FMR4 are co-expressed in some but not
all of the human adult tissues examined.
Found at: doi:10.1371/journal.pone.0001486.s001 (0.38 MB TIF)
Figure S2 Bioinformatic analysis of the genomic DNA sequence
encompassing FMR4.
Found at: doi:10.1371/journal.pone.0001486.s002 (0.17 MB
DOC)
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